Other, containing antimalarial active principles described in Sub-heading Note 2 to this Chapter
Antimalarial medicaments in measured doses for retail sale
HSN 3004 60 00 (antimalarial medicaments containing active principles described in Sub-heading Note 2 to Chapter 30) requires Central Drugs Standard Control Organisation (CDSCO) drug registration and an Import Licence for Drugs under the Drugs and Cosmetics Act, 1940. The Directorate General of Foreign Trade (DGFT) classifies this tariff line as subject to ITC (HS) policy controls, and import of oxytocin — where it falls within this heading — is prohibited under S.O. 2357(E) and DGFT Notification 09/2015-2020 dated 23-05-2022, with the sole exception of oxytocin reference standards for test and analysis.
- Registration certificate from CDSCO
- Import licence for drugs from CDSCO
- Batch release certificate from CDSCO
Procedural directions for customs clearance are issued by: Directorate General of Foreign Trade.
- 1Obtain a valid drug registration certificate (document code 101dc1) and an Import Licence for Drugs (document code 9111dc) from the Central Drugs Standard Control Organisation before filing the bill of entry. Both documents must be uploaded in e-Sanchit; customs out-of-charge will not be granted until the proper officer verifies their presence.Drugs and Cosmetics Act, 1940 · document codes 101dc1 and 9111dc (CCR e-Sanchit mandate)
- 2Upload the Certificate of Analysis for drugs (document code 0010dc), Batch Release Certificate (document code 0030dc), and Label of Consignment (document code 0110dc) in e-Sanchit at the bill of entry stage. These are mandatory pre-out-of-charge documents regardless of whether the bill is PGA-facilitated.CCR e-Sanchit mandate · document codes 0010dc, 0030dc, 0110dc
- 3Confirm the active principle being imported is not oxytocin: import of oxytocin is prohibited under S.O. 2357(E) and DGFT Notification 09/2015-2020 dated 23-05-2022. The sole permitted exception is import of oxytocin reference standards exclusively for test and analysis, conditional on submission of a test licence issued by DGCI/CDSCO.S.O. 2357(E) · DGFT Notification 09/2015-2020 dated 23-05-2022
The most common error on this tariff line is failing to verify the precise active principle against the Sub-heading Note 2 scope before classification — antimalarial medicaments falling under 3004 60 00 must contain only the active principles enumerated in Sub-heading Note 2, and any misclassification that obscures an oxytocin-containing product (which is prohibited) exposes the importer to confiscation and prosecution. Where the consignment contains oxytocin reference standards, the DGCI/CDSCO-issued test licence is a hard documentary precondition; absence of that licence at the bill of entry renders the import unlawful, not merely procedurally deficient.